These results tout the potential Eli Lilly's Taltz-Zepbound as the new SoC for PsA patients with comorbid obesity.

In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.

In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...

Treatment with the tumour necrosis factor receptor 2 (TNFR2)-targeting monoclonal antibody (mAb) plus Keytruda was also found ...

While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.

MetaVia will now be investigating the candidate at two different titration levels in 16-week trials for obesity.

The PRISM process analyses electronic health records, medical histories, diagnoses, and clinical characteristics to determine patient trial eligibility. Credit: Mount Sinai. The Mount Sinai Tisch ...

The decision to end the trial was based on an interim analysis that showed a numerically lower favourable response rate and a numerically higher mortality rate in the opelconazole arm. Image credit: ...